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Abstract
Background: Actinobacillus pleuropneumoniae, the causative agent of porcine pleuropneumonia, is
a highly contagious respiratory pathogen that causes severe losses to the swine industry
worldwide. Current commercially-available vaccines are of limited value because they do not
induce cross-serovar immunity and do not prevent development of the carrier state. Microarray-
based comparative genomic hybridizations (M-CGH) were used to estimate whole genomic
diversity of representative Actinobacillus pleuropneumoniae strains. Our goal was to identify
conserved genes, especially those predicted to encode outer membrane proteins and lipoproteins
because of their potential for the development of more effective vaccines.
Results: Using hierarchical clustering, our M-CGH results showed that the majority of the genes
in the genome of the serovar 5 A. pleuropneumoniae L20 strain were conserved in the reference
strains of all 15 serovars and in representative field isolates. Fifty-eight conserved genes predicted
to encode for outer membrane proteins or lipoproteins were identified. As well, there were
several clusters of diverged or absent genes including those associated with capsule biosynthesis,
toxin production as well as genes typically associated with mobile elements.
Conclusion: Although A. pleuropneumoniae strains are essentially clonal, M-CGH analysis of the
reference strains of the fifteen serovars and representative field isolates revealed several classes of
genes that were divergent or absent. Not surprisingly, these included genes associated with capsule
biosynthesis as the capsule is associated with sero-specificity. Several of the conserved genes were
identified as candidates for vaccine development, and we conclude that M-CGH is a valuable tool
for reverse vaccinology.
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Background
Actinobacillus pleuropneumoniae is a Gram-negative bacte-
rium belonging to the family Pasteurellaceae. It is the etio-
logical agent of porcine pleuropneumonia, a highly
contagious respiratory infection that causes severe eco-
nomic losses to the swine industry worldwide. The dis-
ease, transmitted by the aerosol route or direct contact
with an infected pig, is characterized by hemorrhagic,
fibrinous and necrotic lung lesions [1-3]. The clinical pic-
ture may range from peracute to chronic and asympto-
matic carrier pigs can transmit the disease when
introduced into uninfected herds. Two different biovars
are recognised within the species: biovar 1 strains are nico-
tinamide adenine dinucleotide (NAD) dependent while
biovar 2 strains are NAD-independent [4,5]. Based on
capsular polysaccharides and lipopolysaccharide (LPS) O-
chain components, 15 serovars have been described. Sero-
vars 1 to 12 and 15 usually belong to biovar 1; whereas
serovars 13 and 14 isolates are typically biovar 2 [5-8],
however, biovar 2 variants of serovar 2, 4, 7 and 9 have
been reported [5,9,10].
Serotyping and other genetic typing methods for A. pleu-
ropneumoniae have contributed greatly to surveillance and
epidemiological studies. These tools provide important
information for decision making in control programs
aimed at eradication of virulent types of the bacterium.
Nevertheless, serological cross-reactivity between A. pleu-
ropneumoniae serovars 1, 9 and 11 [11], between serovars
3, 6 and 8 [12], and between 4 and 7 [13] has been
described. In North America, serovars 1, 5 and 7 are
reported to be the most prevalent, while serovars 2 and 9
are most commonly isolated in Europe, and serovar 15 is
the predominant isolate from Australian pigs [14-16].
The virulence factors described for A. pleuropneumoniae
include LPS, capsular polysaccharides, Apx toxins (I-IV),
outer membrane proteins (OMPs) and various iron acqui-
sition systems. However, the overall contribution of each
component to the infection process remains unclear, as
do the mechanisms of pathogenesis of this organism [16-
18]. All serovars are capable of causing disease; however,
some serovars such as serovars 1, 2, 5a, 5b, 9 and 11 are
more frequently involved in severe outbreaks with high
mortality and pulmonary lesions. Several reports have
suggested that the differences in virulence among the sero-
vars can mainly be attributed to different combinations of
Apx toxins and the amount of capsular polysaccharides
[17,19-21]. Almost all of the currently available vaccines
against A. pleuropneumoniae are either inactivated whole-
cell bacterins or subunit combinations of Apx toxins and
proteins or OMPs [22]. Experimental challenge and field
usage data indicate that these vaccines neither induce
cross-serovar immunity nor prevent development of the
carrier state and have little impact on morbidity [23-26].
Molecular techniques, including Multilocus Enzyme Elec-
trophoresis (MLEE) [27,28], Pulsed-Field Gel Electro-
phoresis (PFGE) [29] and Amplified Fragment Length
Polymorphism (AFLP) analysis [30] have been used to
study different strains of A. pleuropneumoniae. These inves-
tigations have shown that genetic diversity among isolates
of the same serovar may be almost equivalent to that in
the species as a whole, suggesting that A. pleuropneumoniae
strains are genetically very similar and would seem to have
a clonal population structure. However, restriction analy-
sis fingerprinting [31,32] studies revealed that with the
exception of serovars 1 and 9, the reference strains of A.
pleuropneumoniae are clearly different. Similarly, work of
Chevallier et al. and Møller et al. revealed a more pro-
nounced heterogeneity in the chromosomal structure
among strains of serovars 1, 5a, 5b, 7, 8 and 12 [27,29].
The notion of heterogeneity amongst serovars is also sup-
ported by early free-solution DNA-DNA hybridization
studies that showed that representative strains of 12 sero-
vars of A. pleuropneumoniae shared 74 to 90% sequence
homology with A. pleuropneumoniae serovar 1 [32].
We are using a reverse vaccinology approach to identify
new candidates for the development of cross-protective
vaccines against A. pleuropneumoniae. Using the complete
and annotated A. pleuropneumoniae L20 genome [33],
Chung and coworkers published a list of 93 predicted
OMPs or lipoproteins of A. pleuropneumoniae obtained by
using five genome scanning programs [34]. The availabil-
ity of the genome sequence of A. pleuropneumoniae also
enables us to study diversity of A. pleuropneumoniae on a
genome-wide scale. To date, two additional complete
genomic sequences have become available, A. pleuropneu-
moniae serovar 3 JL03 [GenBank:CP000687] [35], and A.
pleuropneumoniae serovar 7 AP76 [GenBank:CP001091].
M-CGH is a powerful tool to estimate whole genomic
diversity and to study the gene content and locate
genomic islands in closely related strains of bacteria [36-
42]. In the present study, this method was applied for the
first time to study genetic relationships among reference
strains of the 15 serovars of A. pleuropneumoniae and rep-
resentative field isolates. Our goal was to identify con-
served genes with particular emphasis on those predicted
to encode outer membrane proteins and lipoproteins
because of their potential for the development of
improved vaccines.
Results and Discussion
The first microarray-based study of A. pleupneumoniae,
which used a full-genome microarray based upon a draft
version of the genome sequence of strain L20, evaluated
the effects of iron limitation [43]. From the recently com-
pleted genome sequence of A. pleuropneumoniae L20 [33],
a full genome A. pleuropneumoniae microarray (AppChip2;BMC Genomics 2009, 10:88 http://www.biomedcentral.com/1471-2164/10/88
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GEO Accession Number GPL6658), which takes into
account corrections from the draft sequence and com-
prises reporters matching the sequence of more than 1800
genes, was developed and used in this study. With micro-
array hybridization, the presence of a specific gene in a test
strain is based on comparison of the intensity of the
hybridization signal obtained with the genomic DNA of
the tester strain to that obtained with the genomic DNA of
the control strain for the corresponding reporter. The ratio
of intensity of tester signal to control signal is usually
expressed on a log2 scale and we used a threshold of -1 to
define genes likely to be divergent in sequence from the
strain L20 genome. We have shown previously that genes
absent from the tested strain usually have log2 ratio values
less than -3 [37]. The overall genomic variability of the 15
A. pleuropneumoniae serovars is shown in Figure 1 where
the number of serovars in which a gene is variable is plot-
ted for each gene with the gene order corresponding to the
strain L20 genome sequence. Although most genes are
conserved across the 15 serovars, we observed a number
of distinct clusters of absent/divergent genes. A total of
205 genes were identified as either divergent or highly
divergent/absent in the 15 reference strains tested (addi-
tional file 1). In the largest cluster (APL_0488 to
Number of reference strains representing the 15 serovars of A. pleuropneumoniae where gene is divergent or missing for each  gene, ordered as in A. pleuropneumoniae L20 genome sequence and based on M-CGH results Figure 1
Number of reference strains representing the 15 serovars of A. pleuropneumoniae where gene is divergent or 
missing for each gene, ordered as in A. pleuropneumoniae L20 genome sequence and based on M-CGH results. 
(Blue: -3<Log2Ratio<-1, Red: Log2Ratio<-3). RM, DNA restriction/modification enzymes; TNP, transposon; LPS, lipopolysac-
charide biosynthesis genes; RTX, toxin genes; CHO, carbohydrate biosynthesis genes.
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APL_0525), many genes are annotated as potential phage
or prophage genes, suggesting that this cluster might cor-
respond to a phage. A smaller cluster around APL_0947 to
APL_0952 corresponds to genes annotated as transposon-
related. Several of the other clusters correspond to genes
annotated as components of DNA restriction and modifi-
cation systems. Clusters of variable genes involved in
toxin production, and in capsule and LPS biosythesis were
observed as expected. Several other clusters containing
unannotated genes may warrant further investigation.
Experiments with closely related bacterium Actinobacillus
suis showed only weak hybridization to the AppChip2
microarray, suggesting that the nucleotide sequence iden-
tities for the ORFs are low; consistent with earlier DNA-
DNA hybridization studies [32] (data not shown).
We used hierarchical clustering based on the M-CGH
results to examine the relationship between A. pleuropneu-
moniae serovars based on genomic content. The dendro-
gram of the data excluding phage and transposon-related
genes is shown in Figure 2. This tree has very similar struc-
ture to the tree based on data from all 1857 genes on
AppChip2 (data not shown), and both show serovars 5a
and 5b forming a distinct subclade. Also, the antigenically
related serovars 1, 11, and 9 cluster together as do cross-
reactive serovars 4 and 7. Nevertheless we do not observe
clustering of serovars 1, 5 and 7 which are the most com-
mon ones found in North America or of serovars 13 and
14 which represent biovar 2.
The M-CGH patterns for capsule biosynthesis genes (Fig-
ure 3A) show a high degree of variability for the various
serovars compared to serovar 5b. This is to be expected as
the capsule is a major determinant of the A. pleuropneumo-
niae serovar [6,44]. Much less variation across serovars is
observed with the cpx genes which are involved in capsule
export than with the cps and kds genes which are involved
in capsule biosynthesis.
Serotyping of A. pleuropneumoniae is based mainly on the
capsular polysaccharide (CPS) and the lipopolysaccharide
antigenic O-chain component [44]. The M-CGH patterns
for capsule biosynthesis genes (Figure 3A) show a high
degree of variability for the various serovars compared to
serovar 5b, except for serovar 5a. The structures of CPS
from subtypes 5a and 5b have been determined [45,46].
Both structures share a common backbone consisting of
disaccharide repeating units, [→6)-α-D-GlcpNAc(1→5)-
β-KDOp-(2→]n. In addition, the CPS of serovar 5b has a
lateral β-D-glucopyranosyl residue [45]. Moreover, both
subtypes contain LPS 0-chain components with the same
basic polysaccharide structure of a linear unbranched
homopolymer of 1,6-linked β-D-galactopyranosyl resi-
dues [47]. Thus, the related structures of the capsular
polysaccharides of subtypes 5a and 5b are consistant with
the identical M-CGH patterns for capsule biosynthesis
genes for these two serovars.
The M-CGH pattern of toxin biosynthesis genes for the
reference strains of the 15 serovars is shown in Figure 3B.
The pattern observed for the toxin genes is in agreement
with the results of Frey and co-workers [48] who reported
that the apxIDB genes are missing in serovar 3; apxIAC are
missing in serovars 2, 3, 4, 6, 7, 12, 13 and 15; apxIIAB
genes are missing in serovars 10 and 14. Consistent with
previous reports [49-51], apxIVA was present in all serov-
ars; as apxIII genes are not present in A. pleuropneumoniae
serovar 5 strains (including L20) they were therefore not
included on the AppChip2 microarray.
The genomic variability of 15 representative field isolates
of A. pleuropneumoniae serovars 1, 7 and 15 is shown in
Figure 4. For each serovar, the number of strains in which
a gene is variable is plotted for each gene with the gene
order corresponding to the strain L20 genome sequence.
For serovars 5a, we observed only one cluster of highly
variable genes which is the largest cluster (APL_0488 to
APL_0525) containing many genes annotated as potential
phage or prophage genes in serovar 5b.
To evaluate relationships among the 21 field isolates of
serovars 1, 5, 7 and 15 and their respective reference
strains, we performed hierarchical clustering to build den-
drograms based upon analysis of the data excluding phage
and transposase genes (Figure 5). Except for serovar 7,
strains from the same serovar formed a cluster. The analy-
sis indicated that the Ontario serovar 7 field isolates 881
and 1951 clustered separately from the Quebec and Sas-
Hierarchical clustering of A. pleuropneumoniae reference  strains based on M-CGH data excluding phage and trans- posase genes Figure 2
Hierarchical clustering of A. pleuropneumoniae refer-
ence strains based on M-CGH data excluding phage 
and transposase genes. The dendrogram was produced 
using the MEV software from the J. Craig Venter Institute 
with Euclidean distance and average linkage clustering (n = 
1000 bootstrap iterations).BMC Genomics 2009, 10:88 http://www.biomedcentral.com/1471-2164/10/88
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Variability of genes involved in toxin and capsule biosynthesis across the A. pleuropneumoniae reference strains representing the  15 serovars Figure 3
Variability of genes involved in toxin and capsule biosynthesis across the A. pleuropneumoniae reference strains 
representing the 15 serovars. Green indicates that the gene is divergent in sequence or absent in the tester strain.
B Toxin  genes
A  Capsule biosynthesis genes
/ cps5ABMC Genomics 2009, 10:88 http://www.biomedcentral.com/1471-2164/10/88
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katchewan serovar 7 strains. In contrast, Ontario and Sas-
katchewan serovar 1 field isolates were genetically very
similar. As expected, the eight serovar 5a and 5b strains
form a distinct cluster. These results are consistent with
earlier restriction endonuclease fingerprinting analysis,
which revealed limited heterogeneity amongst isolates of
serovar 1 or serovar 5 whereas serovar 7 isolates showed
greater variation [31].
In Canada, the most prevalent serovars are 1, 5 and 7.
However, other serovars have also been isolated from spo-
radic outbreaks of pleuropneumonia. This is the first
report describing the isolation and characterization of
serovar 15 strains from field cases of porcine pleuropneu-
monia in North America. In previous reports, serovar 15
strains have only been isolated from pigs in Australia and
Japan [15,52]. Hierarchical clustering based on our M-
CGH results showed that the three serovar 15 field strains
(05–13146, 05–14657, 05–20080) are closely related to
the reference strain of serovar 15 of A. pleuropneumoniae.
These three serovar 15 field strains also had the same M-
CGH pattern of toxin biosynthesis genes as reported for
serovar 15 field strain isolated in Japan [52] and the refer-
ence strain (HS143). In these strains the Apx structural
genes, apxIIA, apxIIB and apxIVA, but not apxIA and apxIC,
and Apx secretion genes apxIBD were detected (data not
shown).
Number of strains from 15 fresh field isolates of A. pleuropneumoniae serovars 1, 7 and 15 where the sequence is divergent or  absent for each gene, ordered as in A. pleuropneumoniae L20 genome sequence and based on M-CGH results Figure 4
Number of strains from 15 fresh field isolates of A. pleuropneumoniae serovars 1, 7 and 15 where the sequence 
is divergent or absent for each gene, ordered as in A. pleuropneumoniae L20 genome sequence and based on M-
CGH results.
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APL_0001          APL_010            APL_019             APL_0297           APL_0394          APL_0489          APL_0584
APL_0682          APL_0773          APL_0864           APL_0968           APL_1065          APL_1160          APL_1250
APL_1348         APL_1447           APL_1545          APL_1642          APL_1744           APL_1851          APL_1949        APL_2046
Serotype 7
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APL_1348         APL_1447          APL_1545         APL_1642   APL_1744          APL_1851          APL_1949         APL_2046
Serotype 15
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APL_0682         APL_0773          APL_0864           APL_0968          APL_1065          APL_1160          APL_1250
APL_1348         APL_1447          APL_1545          APL_1642          APL_1744          APL_1851          APL_1949         APL_2046
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The serologically non-typeable isolate, 05–15225, pos-
sessed the same M-CGH pattern of toxin biosynthesis
genes as the reference strains of serovars 5a and 5b. The M-
CGH pattern for capsule biosynthesis genes of the 05–
15225 isolate showed little variability compared to sero-
var 5b. Only two genes involved in capsule biosynthesis,
cpsC and cpsD had a log2 ratio value less than -1. These
two genes may be deleted or diverged in sequence in this
isolate, which could explain why it was not typable by
serology. Nevertheless, the dendrogram showed that 05–
15225 isolate is closely related to the serovar 5 (subtypes
a and b), suggesting that it can be classified in serovar 5
strains.
Other clustering methods or distances were applied to the
data set in order to verify that the clusters we identified
were robust (data not shown). Hierarchical clustering
with Manhattan Distance metrics and K-Medians Cluster-
ing (K-MC) [53] yielded highly similar results: strains
from the same serovar clustered together, with the serovar
7 strains from Ontario grouped with serovar 15 strains,
although the serotype 15 13146 strain was left on its own
following K-Medians Clustering. In both cases, the non-
typeable 05–15225 isolate clustered with serovar 5
strains. Cluster Affinity Search Technique [54] generated
the same results, however serovar 15 strains were scattered
in three different clusters, and were not grouped with
serovar 7 strains from Ontario.
Commercially available vaccines against A. pleuropneumo-
niae, including inactivated whole-cell bacterins and subu-
nit vaccines, have limited efficacy and little impact on
morbidity. Moreover, these vaccines confer only partial
protection against the homologous serovar and generally
do not confer protection against challenge with heterolo-
gous serovars [55-57]. A major focus of research for the
development of new vaccines against porcine pleurop-
neumonia has been to identify proteins that are conserved
in all 15 serovars of A. pleuropneumoniae and that generate
cross-protection against strains of all serovars. Based on
the principle that surface-exposed antigens are more sus-
ceptible to recognition by antibodies and therefore are the
most suitable candidates for a vaccine, the full genome of
A. pleuropneumoniae L20 was screened using bioinformat-
ics predictor programs to identify open reading frames
encoding putative proteins localized at the bacterial outer
membrane and 45 OMPs and 48 lipoproteins were pre-
dicted [34]. Using M-CGH to identify genes that are
highly conserved among the reference strains of the 15
serovars of A. pleuropneumoniae, as well as among field iso-
lates, we identified 58 potential vaccine targets (24 OMPs
and 34 lipoproteins) (Table 1) that are conserved among
Hierarchical clustering of field isolates of A. pleuropneumoniae based on M-CGH data excluding phage and transposase genes Figure 5
Hierarchical clustering of field isolates of A. pleuropneumoniae based on M-CGH data excluding phage and 
transposase genes.
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all serovars and biovars. Among these candidates, four
have been shown to be expressed in vivo. Using selective
capture of transcribed sequences analysis (SCOTS) [58], it
has been shown that ompA (APL_1421) and APL_0829 are
expressed by A. pleuropneumoniae in necrotic pig lung tis-
sue. Furthermore, polyamine transport protein D
(APL_0368), Omp P2 (APL_0649), OmpA (APL_1421)
and outer membrane antigenic lipoprotein B (APL_1930)
are required for efficient colonization of the porcine host
by  A. pleuropneumoniae as shown by signature-tagged
mutagenesis (STM) experiments [59,60].
A. pleuropneumoniae bind preferentially to cells of the
lower respiratory tract, where some essential nutrients for
the growth of bacteria, such as iron, are limited. A. pleurop-
neumoniae  has developed several iron uptake systems
including the hydroxamate siderophore receptor FhuA
(APL_2016), a hemoglobin-binding receptor HgbA
(APL_1047) and a transferrin receptor complex composed
of two outer membrane proteins, transferrin-binding pro-
tein A (TbpA; APL_1567) and transferring-binding pro-
tein B (TbpB; APL_1568). Not only is iron essential for
growth of bacteria but iron-restriction is an important sig-
nal that controls expression of many genes including
some coding for virulence factors [43]. Hence, these pro-
teins involved in iron uptake are considered as candidates
for development of subunit vaccines. However, our M-
CGH results showed that only one protein involved in
iron uptake, TbpA, is conserved among the 15 serovars of
A. pleuropneumoniae. This observation could explain the
partial protection against infection with heterologous
strains conferred by an acellular pentavalent subunit vac-
cine containing the TbpB of A. pleuropneumoniae serovar 7
[26].
The NADPH-sulfite reductase hemoprotein CysI
(APL_1842) of A. pleuropneumoniae, a cytoplasmic protein
involved in cellular metabolism, has also been shown to
induce protective immunity against a homologous chal-
lenge [61]. Our CGH analysis showed that CysI is con-
served among all strains tested in this study, thus this
protein could represent an interesting vaccine target.
Two genes (APL_1421  and  APL_1852), encoding
homologs of outer membrane protein A (or OMP P5),
were identified as potential vaccine targets in this study.
Table 1: A. pleuropneumoniae reference strains and field isolates analyzed by M-CGH in this study.
Strains Serovars Source
Reference strains All from K.R. Mittal1
S4074 1
S1536 2
S1421 3
M62 4
K17 5a
L20 5b
Femø 6
WF83 7
405 8
CVJ 13261 9
13069 10
56153 11
8329 12
N273 13
3906 14
HS143 15
Field strains
05–7430, 05–7431 1 M. Ngeleka 2
719, 2398, 2521 1 D. Slavic3
04–37943, 04–3128, 05–508 5a M. Ngeleka 2
04–14796, 03–22382, 03–22383 5b M. Ngeleka 2
05–3695, 06–3060 7 S. Messier1
04–13054, 05–14401 7 M. Ngeleka 2
881, 1951 7 D. Slavic3
05–13146, 05–14657, 05–20080 15 M. Ngeleka 2
05–15225 non-typeable M. Ngeleka 2
1 Faculté de médecine vétérinaire, Université de Montréal, St-Hyacinthe, QC
2 Prairie Diagnostic Services, University of Saskatchewan, Saskatoon, SK
3 Ontario Veterinary College, University of Guelph, Guelph, ONBMC Genomics 2009, 10:88 http://www.biomedcentral.com/1471-2164/10/88
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APL_1421 and APL_1852 have 70.6% identity and
showed 75.6% and 70.6% identity, respectively, to OmpA
from the bovine pathogen Mannheimia haemolytica, which
has surface exposed epitopes and is recognized by conva-
lescent bovine sera [62,63]. In addition to ompA
(APL_1421), the outer-membrane lipoprotein LolB
(APL_0777), is expressed in vivo by A. pleuropneumoniae
and they have been identified and characterized as poten-
tial components of a cross-protective sub-unit vaccine
against A. pleuropneumoniae [64]. However, Oldfield et al.
reported that neither of these proteins was capable of elic-
iting protective immunity against A. pleuropneumoniae
challenge [64]. The outer membrane protein PalA
(APL_0304) was also on our list of conserved proteins.
Nevertheless, it has been shown that vaccination with
PalA increases the severity of A. pleuropneumoniae infec-
tion in vaccinated pigs [65]. Thus, the deleterious effect of
PalA in vaccination and the inability of LolB and OmpA
to induce protective immunity eliminate these proteins
from the list of potential vaccine candidates.
Interestingly, homologs of some of the remaining con-
served vaccine candidates are already under investigation
as vaccine components in other bacteria (including other
Pasteurellaceae). For example, the lipoprotein Plp4 from
M. haemolytica, which had 85.3% identity with lipopro-
tein PlpD (APL_0460), was identified by screening anti-
gens of M. haemolytica with sera from Presponse™
vaccinated calves (a cell-free culture supernatant M.
haemolytica  A1 vaccine) that were protected from M.
haemolytica A1 infections [66], thus suggesting PlpD may
be a protective antigen. Another candidate, APL_0378, a
glycerophosphodiester phosphodiesterase (GlpQ),
showed 82% and 79.5% identity to GlpQ of Pasteurella
multocida and protein D of Haemophilus influenzae, respec-
tively. The role of GlpQ in A. pleuropneumoniae and P. mul-
tocida is unknown, however, its homolog in H. influenzae
has been shown to mediate the acquisition of choline
directly from the membranes of epithelial cells in culture
and incorporate it into its own LPS [67]. H. influenzae pro-
tein D has been showed to elicit cross-protection against
virulent heterologous strains of H. influenzae in rats [68].
In contrast to H. influenzae, GlpQ in P. multocida is not
surface-exposed and is unable to stimulate protective
immunity, even though vaccinated animals have high
antibody titers [69]. Therefore, the location of GlpQ and
accessibility of GlpQ-specific antibodies should be deter-
mined in A. pleuropneumoniae.
OMP P4 (ompP4; ALP_0389) is another attractive surface
exposed antigen [70] showing 65% identity to lipoprotein
E (also known as OMP P4) in H. influenzae, which is
highly conserved among both typeable and nontypeable
strains [71]. In nontypeable strains of H. influenzae
(NTHi), OMP P4 is essential for utilization of NAD and
subsequent growth [72,73]. Intranasal immunization of
mice with OMP P4 in a mucosal adjuvant induces protec-
tive immune responses against NTHi infections and nota-
bly, a mucosal immune response, which reduces NTHi
nasopharynx colonization [74]. These observations in H.
influenzae suggest that lipoprotein E (APL_0389) may be
an attractive candidate for a vaccine against A. pleuropneu-
moniae.
PCP (peptidoglycan-associated lipoprotein cross-reacting
protein) of H. influenzae is under investigation since it is
surface-exposed and anti-PCP serum shows bactericidal
activity against several clinical isolates of type b and non-
typeable H. influenzae [75]. Outer membrane lipoprotein
SlyB (APL_0037) shows highest identity (71.4%) to this
protein. However, although PCP from P. multocida (also
surface-exposed) is recognized by convalescent chicken
antiserum, it is unable to stimulate protective immunity
[69].
The polyamine transport protein D, PotD (APL_0368),
has extensive homology to a 38 kDa lipoprotein, Lpp38 of
M. haemolytica. Lpp38 is surface-exposed and is recog-
nized by sera from calves resistant to infection after natu-
ral exposure to M. haemolytica and by sera from calves
vaccinated with M. haemolytica A1 outer membranes or
with live bacteria [76]. Recently, in the human pathogen
Streptococcus pneumoniae, PotD has been reported to be
involved in virulence in both an animal model of sepsis
and pneumonia [77,78]. Active immunization of mice
with recombinant PotD induces a vigorous antibody
response and provides a significant degree of protection
against lethal pneumococcal infection [79]. These data
suggest that PotD plays a role in the development of
immunity to bacterial infections and may be a protective
antigen.
Homologs of the outer membrane protein D15
(APL_0411) have been reported in several pathogenic
bacteria including H. influenzae, Haemophilus ducreyi, P.
multocida,  Neisseria meningitidis and  Shigella dysenteriae
[80-83]. These studies suggest a role for these proteins in
pathogenesis and immunity. Notably, it has been shown
that D15 confers protection against homologous and het-
erologous strains of H. influenzae in animal models [84-
86]. Similarly, Oma87, a closely related homolog in P.
multocida, has been shown to elicit protection in animal
model of infection [83]. Thus D15 is potentially an attrac-
tive vaccine target.
Conclusion
In this study, we have shown that M-CGH can be a useful
tool to identify candidates for reverse vaccinology in order
to develop subunit vaccines to A. pleuropneumoniae. After
comparing CGH data for 15 reference strains and 21 freshBMC Genomics 2009, 10:88 http://www.biomedcentral.com/1471-2164/10/88
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field isolates, we have identified 58 conserved genes that
are predicted to code for outer membrane proteins or
lipoproteins. This could assist in development of vaccines
with efficacy across serovar boundaries. Future investiga-
tions will include the use of microarray transcript profil-
ing experiments of A. pleuropneumoniae isolated from
infected pigs to identify potential vaccine candidates that
are both conserved and expressed in vivo during infection
in pigs.
Methods
Bacterial strains
Reference strains and field isolates of A. pleuropneumoniae
used in this study are listed in Table 2. All A. pleuropneu-
moniae strains were inoculated into Brain-Heart Infusion
(BHI, Difco Laboratories, Detroit, MI) medium supple-
mented with NAD: either 15 μg/ml in agar or 5 μg/ml in
broth. Cultures were grown at 37°C for 16–18 hours
before genomic DNA isolation.
Construction of an A. pleuropneumoniae amplicon-based 
DNA microarray (AppChip 2)
PCR primers were designed for 1954 genes of the A. pleu-
ropneumoniae L20 (serovar 5b) genome using the Primer3
program [87] controlled by an automated script as
described previously [make_primers code available at
http://www.ibs-isb.nrc-cnrc.gc.ca/glycobiology/
group_software_e.html] [88]. Most sequences of length
greater than 2000 nt were split to create two or more
reporters corresponding to a single large ORF. Primer
selection parameters were standardized and included sim-
ilar predicted melting temperature (60 ± 2°C), uniform
length (25 nt), and minimum amplicon size of 160 bp.
Generation of PCR amplicons and fabrication of DNA
microarrays were described previously [88]. Details on the
construction of this microarray (AppChip2) are available
at NCBI (GEO Accession Number GPL6658). The
AppChip2 microarray comprises validated amplicons
covering > 92% of the ORFs longer than 160 bp in the
final  A. pleuropneumoniae L20 genome sequence (Gen-
Bank accession number CP000569).
Isolation of genomic DNA
A. pleuropneumoniae strains were harvested after growth on
agar plates for 16–18 h, resuspended in H2O, and treated
with lysozyme (Roche, Laval, QC) and RNase A (Qiagen,
Mississauga, ON) for 10 min at room temperature. The
cell suspensions were then digested with proteinase K
(MBI Fermentas, Burlington, ON) for 1 h at 37°C, and
complete lysis was obtained by addition of sodium
dodecyl sulfate to a final concentration of 0.1% (wt/vol).
Genomic DNA, extracted from the cell lysates by two
extractions with phenol-chloroform-isoamyl alcohol
(25:24:1) and two extractions with chloroform, was pre-
cipitated in ethanol.
Genomic DNA labelling
Isolated genomic DNA was fragmented by nebulization.
One hundred μg of DNA in H2O and 35% glycerol (v/v)
was placed in an AeroMist Nebulizer chamber (IPI Medi-
cal Products, Chicago, IL), and sheared by passing nitro-
gen gas through the chamber at 15 psi for 1 min. The DNA
was precipitated with ethanol and suspended in 100 μl of
ddH2O. Typically, the DNA was fragmented to a range of
0.4 to 12 kb in size. Five μg of fragmented DNA were flu-
orescently labeled using direct chemical coupling with the
Label-IT (Mirus Corp., Madison, WI) cyanine dyes Cy3
and Cy5 as recommended by the manufacturer. Probes
were purified from unincorporated dyes by passing sam-
ples through Qiaquick columns (Qiagen, Mississauga,
ON). Labeled DNA sample yields and dye incorporation
efficiencies were assessed using a Nanodrop ND-1000
spectrophotometer (Nanodrop, Rockland, DE).
Microarray hybridizations
The hybridization profile for each strain was obtained by
co-hybridizing labeled DNA from the tester strain with
labeled DNA from the A. pleuropneumoniae serovar 5b
(L20) control strain to the microarray. DNA from tester
strains was labeled with Cy3 and DNA from the control
strain with Cy5. Dye swaps were performed on selected
strains to test for any dye-incorporation bias. Labeled
samples were normalized by selecting tester/control sam-
ple pairs with similar dye incorporation efficiencies.
Equivalent amounts (2 μg) of labeled tester and control
samples were pooled, lyophilized, and then re-suspended
in 42 μl of hybridization buffer [1 × DIGEasy hybridiza-
tion solution (Roche Applied Science); 0.5 μg/μl of Torulla
yeast tRNA (Invitrogen); 0.5 μg/μl of salmon sperm
genomic DNA (Invitrogen)]. Labeled gDNA was dena-
tured at 65°C for 5 min and applied to the microarray.
Hybridizations were performed overnight at 37°C under
22 × 40-mm glass cover slips in a high-humidity chamber.
Microarrays were washed 2 × 5 min at 50°C in 1 × SSC
with 0.1% SDS, then 2 × 5 min at 50°C in 0.5 × SSC, and
1 × 5 min at 50°C in 0.1 × SSC. Slides were spun dry (500
× g, 5 min) and stored in lightproof containers until
scanned.
Data acquisition and analysis
After hybridization with labeled gDNA, microarray slides
of the 15 reference serovars were scanned using a
Chipreader laser scanner (BioRad, Mississauga, ON)
according to the manufacturer's recommendations. Spot
quantification, signal normalization and data visualiza-
tion were performed using ArrayPro Analyzer v4.5 (Media
Cybernetics, Silver Spring, MD). Net signal intensities
were obtained by performing local-ring background sub-
traction. "Tester signal" is defined as the signal intensity of
the selected A. pleuropneumoniae reference strains labeled
with appropriate fluorescent dye, while "control signal" isBMC Genomics 2009, 10:88 http://www.biomedcentral.com/1471-2164/10/88
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Table 2: In silico predicted OM proteins and lipoproteins from A. pleuropneumoniae (according to Chung et al. 2007), which are 
conserved amongst the 15 reference strains and the 21 field isolates tested by M-CGH in this study.
OrfID Gene Product
Predicted outer membrane proteins
APL_0006 ompP2A outer membrane protein P2
APL_0049 APL_0049 hypothetical protein
APL_0200 hofQ type II secretory pathway, component HofQ
APL_0245 APL_0245 transferrin binding protein-like solute binding protein
APL_0257 APL_0257 probable outer membrane protein
APL_0276 frpB iron-regulated outer membrane protein B
APL_0304 palA outer membrane protein precursor PalA
APL_0410 APL_0410 hypothetical outer membrane protein
APL_0411 D15 protective surface antigen D15 precursor
APL_0460 plpD lipoprotein Plp4
APL_0565 cirA hypothetical ABC transporter ATP-binding protein
APL_0649 ompP2 Outer membrane protein P2 precursor (OMP P2)
APL_0829 APL_0829 hypothetical protein
APL_0840 APL_0840 predicted outer membrane protein
APL_0919 irp iron-regulated outer membrane protein
APL_0959 APL_0959 hemagglutinin/hemolysin-like protein
APL_0962 ostA organic solvent tolerance protein precursor
APL_1421 ompA outer membrane protein P5 precursor
APL_1567 tbpA transferrin-binding protein 1 Tbp1
APL_1705 APL_1705 FKBP-type peptidyl-prolyl cis-trans isomerase
APL_1815 APL_1815 hypothetical protein
APL_1852 ompA Outer membrane protein P5 precursor (OMP P5)
APL_1921 pgaA biofilm PGA synthesis protein PgaA precursor
APL_2002 APL_2002 hypothetical protein
Predicted lipoproteins
APL_0029 APL_0029 ABC transporter periplasmic protein
APL_0036 APL_0036 hypothetical protein
APL_0037 slyB outer membrane lipoprotein
APL_0116 APL_0116 hypothetical protein
APL_0124 APL_0124 hypothetical protein
APL_0156 apbE thiamine biosynthesis lipoprotein ApbE precursor
APL_0227 APL_0227 hypothetical protein
APL_0236 APL_0236 putative lipoprotein
APL_0332 hlpB lipoprotein HlpB
APL_0356 APL_0356 hypothetical protein
APL_0368 potD2 spermidine/putrescine-binding periplasmic protein 1 precursor
APL_0378 glpQ glycerophosphoryl diester phosphodiesterase
APL_0389 ompP4 lipoprotein E precursor
APL_0428 smpA small protein A
APL_0603 APL_0603 hypothetical protein
APL_0611 APL_0611 putative lipoprotein
APL_0642 mltB membrane-bound lytic murein transglycosylase B
APL_0777 lolB outer-membrane lipoprotein LolB precursor
APL_0816 mltA membrane-bound lytic murein transglycosylase A precursor
APL_0873 rlpB putative rare lipoprotein B
APL_0920 APL_0920 hypothetical protein
APL_1062 APL_1062 hypothetical protein
APL_1121 APL_1121 putative lipoprotein
APL_1152 APL_1152 hypothetical protein
APL_1273 APL_1273 putative fimbrial biogenesis and twitching motility protein PilF-like protein
APL_1297 APL_1297 hypothetical protein
APL_1362 APL_1362 hypothetical protein
APL_1404 oapB opacity associated protein BBMC Genomics 2009, 10:88 http://www.biomedcentral.com/1471-2164/10/88
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defined as the signal intensity of A. pleuropneumoniae
strain 5b labeled with its appropriate fluorescent dye. The
ratio of tester signal to control signal for each gene was
transformed to its base 2 logarithm [89], log2 [Tester Sig-
nal/Control Signal], and is referred to as "Log2Ratio".
Data from each channel were adjusted using cross-chan-
nel Loess normalization of the Log2Ratio data and low
intensity and anomalous spots were flagged and removed.
Data were stored and archived using the BASE BioArray
Software Environment [90]. Microarray data from sets of
hybridizations were exported from BASE after removal of
flagged spots, Loess normalization, and averaging of data
from duplicate spots on the microarray. At least three rep-
licates of each strain were performed and the results aver-
aged.
The microarrays for the A. pleuropneumoniae field strains
were scanned with a Perkin-Elmer ScanArray Express scan-
ner according to the manufacturer's recommendations.
Image and data analysis were performed using TM4 suite
of softwares from the J. Craig Venture Institute [91]. Raw
data were generated using Spotfinder v.3.1.1. The inte-
grated intensities of each spot, equivalent to the sum of
unsaturated pixels in a spot were quantified and the inte-
grated intensity of the local background was subtracted
for each spot. The same operation was performed with the
median spot intensities. Data were normalized with the
MIDAS software tool using cross-channel Loess normali-
zation. Spots with median intensities lower than 1000
were removed from the normalized data set. Intensities
for duplicate spot were merged to generate the final nor-
malized data set. The results were analyzed using the MEV
software, first to check similarity of patterns of gene diver-
gence within replicates for each serovar, then to examine
data averaged across replicates of each serovar. Data were
submitted to the Gene Expression Omnibus
[GEO:GSE11921 and GSE14639].
To evaluate M-CGH results obtained using the different
methods, we compared M-CGH data from A. pleuropneu-
moniae  serovar1 versus serovar 5b hybridizations that
were collected, scanned and processed using ArrayPro
software or SpotFinder/MIDAS software (Figure 6). Excel-
lent correlation between M-CGH data was obtained using
the two different data acquisition and analysis methods.
In cases where more than one reporter on the chip corre-
sponded to a single gene, the data were averaged across
the reporters. Visualization and hierarchical clustering of
microarray data, using Euclidean Distance metrics and
Average Linkage Clustering, was performed in MEV using
algorithms developed by Eisen et al. [92]. To examine the
variation of CGH profiles between the different serovar
strains, we generated sample trees as well as support trees
based on bootstrapping genes with 1000 iterations. Hier-
archical clustering with Manhattan Distance metrics, as
well as K-Median Clustering [53] (5 clusters, 1000 itera-
tions) and Cluster Affinity Search Technique [54] (thresh-
old = 0.55) were also performed in MEV to ensure
robustness of the clusters.
Abbreviations
AFLP: Amplified Fragment Length Polymorphism; BHI:
Brain Heart Infusion; CPS: Capsular Polysaccharide; LPS:
Lipopolysaccharide; M-CGH: Microarray-based Compara-
tive Genomic Hybridization; MLEE: Multilocus Enzyme
APL_1741 mltC Membrane-bound lytic murein transglycosylase C precursor
APL_1875 APL_1875 hypothetical protein
APL_1898 APL_1898 hypothetical protein
APL_1913 pepO neutral endopeptidase
APL_1930 APL_1930 Outer membrane antigenic lipoprotein B precursor
APL_1957 APL_1957 Lipoprotein_5 domain containing protein
Table 2: In silico predicted OM proteins and lipoproteins from A. pleuropneumoniae (according to Chung et al. 2007), which are 
conserved amongst the 15 reference strains and the 21 field isolates tested by M-CGH in this study. (Continued)
Comparison between M-CGH Log2Ratio data from A. pleu- ropneumoniae serovar 1 versus serovar 5b hybridizations  independently collected, scanned and processed using either  ArrayPro software or SpotFinder/MIDAS software Figure 6
Comparison between M-CGH Log2Ratio data from 
A. pleuropneumoniae serovar 1 versus serovar 5b 
hybridizations independently collected, scanned and 
processed using either ArrayPro software or Spot-
Finder/MIDAS software. At least 2 independent hybridi-
zations were performed for each dataset, and the processed 
normalized data was averaged between replicate experi-
ments and between pairs of duplicate spots on the microar-
ray.
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Electrophoresis; NAD: Nicotinamide Adenosine Dinucle-
otide; OMP: Outer Membrane Protein; ORF: Open Read-
ing Frame; PFGE: Pulsed-Field Gel Electrophoresis.
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